Darolutamide with ADT cuts death risk by half in metastatic hormone‑sensitive prostate cancer
A recent study evaluated darolutamide combined with androgen deprivation therapy in patients with metastatic hormone‑sensitive prostate cancer. The trial reported a 50% reduction in the risk of death compared with standard treatment.
The survival benefit was described as statistically significant, indicating that adding darolutamide to ADT can markedly improve overall outcomes for this patient group.
These findings suggest a potential new standard of care for metastatic hormone‑sensitive prostate cancer, pending further regulatory review and broader clinical adoption.
This writeup was produced by pharmadog from original reporting by onclive. The original article may no longer be reachable at its published URL.
Original headline: “Darolutamide Plus ADT Yields Significant OS Benefit in mHSPC”
read at onclive ↗
comments(0)
5-min edit window · permanent after that